MH Survival without Dantrolene

Authors

Wayne R. Simmons DO, HCA HealthcareFollow
Dandan Feng MD, Drum Tower Hospital of Medical School of Nanjiang University in Nanjiang, China
Zhengliang Ma MD, Drum Tower Hospital of Medical School of Nanjiang University in Nanjiang, China
Xiaoping Gu MD
Jeffrey Huang, HCA HealthcareFollow

Division

West Florida

Hospital

Oak Hill Hospital

Document Type

Case Report

Publication Date

8-25-2020

Keywords

malignant hyperthermia, intraoperative complications, postoperative complications, dantrolene, patient safety

Disciplines

Anesthesiology | Critical Care | Pathological Conditions, Signs and Symptoms | Patient Safety

Abstract

Treatment of intraoperative malignant hyperthermia (MH) usually involves administration of IV dantrolene, which reduces the mortality from over 80% if untreated to less than 10%.1 When dantrolene is simply not available, physical and metabolic treatments must be employed. Patient survival is possible, as illustrated in three cases from one hospital in China.

Publisher or Conference

Anesthesia Patient Safety Foundation Newsletter

Recommended Citation

Simmons W, Feng D, Ma Z, Gu X, Huang J. MH Survival without Dantrolene. APSF Newsletter. 2020 August. Online Only. https://www.apsf.org/article/mh-survival-without-dantrolene/